Related Experiment Videos
CT-2584 (Cell Therapeutics)
1Fundacion de Investigacion del Cance, Buenos Aires, Argentina. fundic@velocom.com.ar
Current Opinion in Investigational Drugs (London, England : 2000)
|September 29, 2001
Summary
CT-2584, an anticancer drug inhibiting phospholipid signaling, is in Phase II trials for prostate cancer and soft-tissue sarcoma. Further trials are planned in combination with other chemotherapies.
Area of Science:
- Oncology
- Pharmacology
Background:
- CT-2584 is an investigational anticancer agent developed by Cell Therapeutics Inc. (CTI).
- It functions by inhibiting phospholipid signaling pathways implicated in cancer cell proliferation.
Purpose of the Study:
- To evaluate the safety, pharmacokinetics, and therapeutic activity of CT-2584.
- To explore its potential in treating various cancers, including prostate cancer and soft-tissue sarcoma.
Main Methods:
- Phase II clinical trials are ongoing for prostate cancer and soft-tissue sarcoma.
- Planned trials include Phase II/III combinations with taxotere for prostate cancer and Phase I/II combinations with cisplatin for other cancers like lung cancer.
Main Results:
- Results from a Phase II study in soft-tissue sarcoma patients, assessing pharmacokinetics, tolerance, and therapeutic activity, were presented.
- Additional data presentations are anticipated at the American Society of Clinical Oncology (ASCO) meetings.
Conclusions:
- CT-2584 demonstrates potential as a novel anticancer therapeutic.
- Further clinical development and strategic partnerships are being pursued by Cell Therapeutics Inc.